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The content and organization of mental health care have been heavily influenced by the view that mental difficulties come as diagnosable 
disorders that can be treated by specialist practitioners who apply evidence-based practice (EBP) guidelines of symptom reduction at the group 
level. However, the EBP symptom-reduction model is under pressure, as it may be disconnected from what patients need, ignores evidence of the 
trans-syndromal nature of mental difficulties, overestimates the contribution of the technical aspects of treatment compared to the relational 
and ritual components of care, and underestimates the lack of EBP group-to-individual generalizability. A growing body of knowledge 
indicates that mental illnesses are seldom “cured” and are better framed as vulnerabilities. Important gains in well-being can be achieved when 
individuals learn to live with mental vulnerabilities through a slow process of strengthening resilience in the social and existential domains. In 
this paper, we examine what a mental health service would look like if the above factors were taken into account. The mental health service of 
the 21st century may be best conceived of as a small-scale healing community fostering connectedness and strengthening resilience in learning 
to live with mental vulnerability, complemented by a limited number of regional facilities. Peer support, organized at the level of a recovery 
college, may form the backbone of the community. Treatments should be aimed at trans-syndromal symptom reduction, tailored to serve 
the higher-order process of existential recovery and social participation, and applied by professionals who have been trained to collaborate, 
embrace idiography and maximize effects mediated by therapeutic relationship and the healing effects of ritualized care interactions. Finally, 
integration with a public mental health system of e-communities providing information, peer and citizen support and a range of user-rated 
self-management tools may help bridge the gap between the high prevalence of common mental disorder and the relatively low capacity of 
any mental health service.
Key words: Mental health care, evidence-based practice, relational components of care, public health, resilience, peer support, trans- 
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Mental suffering has been the topic of intense academic re-
search, covering areas of epidemiology, neurobiology, thera-
peutics and health services organization, and giving rise to 
evidence-based practice (EBP) guidelines to achieve symptom 
reduction that can be used for specific diagnosable mental 
disorders.
Evidence-based medicine, in the sense of trying to find out 
what is or is not likely to work for a particular patient, based on 
what is known, makes eminent sense. However, the way in 
which it is (mis)understood and applied may give rise to numer-
ous side effects and limitations, including “cookbook” practice, 
lack of relevance of EBP outcomes for patients, and lack of 
group-to-individual generalizability1-3.
The area of mental disorders, and changes therein over time, 
may be particularly difficult to capture in the conventional 
medical paradigm of diagnosis and treatment-induced symp-
tom reduction at the group level. Nevertheless, according to 
the group-level symptom-reduction principle as applied in 
mental health care, mental suffering comes in the form of uni-
versally diagnosable mental disorders which are of bio-psycho-
social origin and can be classified on the basis of symptoms.
Treatment guidelines are constructed on the basis of me-
ta-analytic evidence of measurable group-level symptom re-
duction, the by far most frequently researched mental health 
treatment outcome4. The professionals who populate mental 
health services have been trained in, first, diagnosing a mental 
disorder in those who seek help for symptoms and, second, 
providing treatment as prescribed by EBP guidelines.
As different disorders have different symptoms, the diag-
nosis-EBP concept as organizing principle of language and 
activities in mental health service systems has contributed 
to diagnostic stratification and specialization of institutions, 
professionals and researchers. Both patients and professionals 
perceive a need for specialized treatments for specific prob-
lems as the primary reference for quality. Consumers know it 
takes time to search the Internet to find a professional who is 
adequately specialized in, for example, autism, bipolar disor-
der, obsessive–compulsive disorder, attention-deficit/hyper-
activity disorder (ADHD), post-traumatic stress disorder or 
borderline personality disorder.
The diagnosis-EBP symptom-reduction model has also im-
pacted health survey technology, which has seen the systemat-
ic application of symptom-based diagnostic criteria for mental 
disorder to the general population, resulting in high rates of 
disorders like major depression and anxiety disorders, landing 
them in the top causes of the global burden of disease.
The total estimated global disease burden of mental illness 
accounts for 21.2% of years lived with disability (YLDs) and 
7.1% of disability-adjusted life-years (DALYs)5, which some 
have argued may represent a substantial underestimation6. 
Given the limited capacity of the mental health system, data 
from the population surveys indicating that yearly prevalence 
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rates of mental disorder are around 20% result in the percep-
tion of much morbidity remaining untreated.
Mental health awareness campaigns, attuned to the diagnosis-
EBP model, have contributed to growing public awareness of the 
existence of diagnosable mental disorders and the importance of 
access to care. Western countries have seen a growing demand 
for treatments, as evidenced by marked increases in the con-
sumption of psychotropic medications such as antidepressants7, 
particularly in young people8, growing use of easy-access manu-
alized non-pharmacological therapy symptom reduction cen-
tres9, and increasing rates of involuntary admissions in European 
countries10.
Within the diagnosis-EBP symptom-reduction perspective, 
the task of mental health services is to “deliver” specialized treat-
ments that should be made available to those who need them, 
regardless of whether the setting is “inpatient” , “outpatient” , or 
“community” treatment.
Countries traditionally differ widely in what mental health 
services do and how they are organized11. It is assumed that 
better mental health services are more “evidence-based”12, 
and that “routine outcome monitoring” of symptom reduction 
can be used to assess the quality of the mental health service. 
However, organizing services around diagnostic specialities 
providing evidence-based symptom reduction implies that the 
diagnosis-EBP group-level symptom-reduction principle is 
valid, relevant and useful, and that group-level findings can be 
translated to individuals3. It also suggests that symptom reduc-
tion is a useful construct as a primary focus in the training of 
professionals and the organization and evaluation of services.
However, “evidence-based” at the group level may not natu-
rally result in patient-centred care at the idiographic level13 
and has been developed around the discourse of diseases and 
symptoms, rather than resilience and possibilities14. The ques-
tion arises to what degree the training of professionals and the 
planning and evaluation of mental health services should also 
be guided by other factors.
In this paper, we discuss a number of issues that are relevant 
in this regard. First, we consider factors that are relevant to the 
validity of the diagnosis-EBP symptom-reduction principle 
in mental health care, such as the trans-syndromal nature of 
psychopathology and the fact that much of the treatment effect 
observed in EBP is, in fact, reducible to contextual components 
that are insufficiently acknowledged and embedded in the ser-
vice and in the training of mental health professionals.
Second, we discuss to what degree organizing services 
around higher-order social, existential and somatic outcome 
domains may potentially be more relevant to users than the 
traditional focus on evidence-based, group-level symptom 
reduction. Third, we point out that, while the high prevalence 
rates of mental disorder indicate the need for a coherent public 
mental health approach, this has not materialized15.
In the final part, we discuss the consequences of these issues 
for the planning, organization and implementation of mental 
health services, and make suggestions for change. Although 
most of the discussion is based on practice as developed in 
high-income countries, we believe that some of the core issues 
are relevant to mental health services worldwide.
THE ADVENT OF TRANS-SYNDROMAL 
FORMULATIONS OF PSYCHOPATHOLOGY 
AND BEYOND
The likelihood ratios for etiology, symptoms, treatment re-
sponse and prognosis, occasioned by traditional diagnostic 
categories, are too low to be considered “useful” as required by 
EBP16-18. Mental difficulties represent highly variable clusters 
of trans-syndromal symptom dimensions that defy detailed 
diagnostic reduction. The use of 10-15 broad and overlapping 
“umbrella” syndromes may be sufficient for daily practice19.
If this is the best “evidence” of classification of psychopa-
thology, should clinicians in mental health services work in 
diagnostic specialization clinics or “care pathways” , or should 
they bring their expertise to impact on trans-syndromal psy-
chopathology, regardless of formal diagnosis?
The perceived value of diagnostic specialization is driven, in 
part, by the possibility of delineation of homogenous groups in 
terms of psychopathology, treatment response and prognosis. 
However, patients with a diagnosis of major depression are hetero-
geneous in terms of symptoms, treatment response and prognosis, 
and show high levels of overlap with patients with other diagnoses 
in terms of symptoms, treatment response and prognosis.
Explicit exclusion criteria in diagnostic systems create a 
higher-order factor of what diagnostic categories are not20, 
resulting in a myriad of categories that may be separately diag-
nosable but at the same time remain strongly correlated with 
each other, resulting in confusingly high “comorbidity” rates 
and poor reliability in clinical practice. This status quo often 
leaves patients as well as referring general practitioners (GPs) 
confused.
A patient-centred trans-syndromal framework that flexibly 
combines categorical, dimensional and network approaches 
may better serve the purpose of maximizing usefulness for dif-
ferent aspects of clinical practice. However, current diagnostic 
specialization in research and clinical practice has given rise to 
a cultural and structural balkanization21 that cannot be read-
ily dismantled, because the professional identity of clinicians 
tends to fuse with these specializations. Changing the status 
quo, i.e. bringing practice more in line with available scientific 
evidence, may thus result in an identity crisis and resistance to 
what may be seen as a non-professional sham.
In order to constructively deal with this issue, the DSM-5 
project attempted to introduce the notion of trans-syndromal 
dimensions across the different chapters, which would have 
opened the way to a new form of trans-syndromal clinical prac-
tice and research. Unfortunately, the project proved too com-
plex and only resulted in some trans-syndromal dimensions 
being included in one of the appendixes. These, however, were 
not truly trans-syndromal, in the sense of cutting across chap-
ters, as all were about within-chapter dimensional variation22.
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In contrast, the US National Institute of Mental Health (NIMH) 
formulated a range of trans-syndromal dimensions of behaviour 
and functioning, with the specific aim to link dimensional vari-
ation to biology in research, but these were not meant for use in 
clinical practice (Research Domain Criteria, RDoC project)23.
The trans-syndromal approach thus remains an attractive op-
tion to bridge the cultural and structural silos that have been built 
around correlated diagnostic categories, but requires more work. 
It may be productive to develop a trans-syndromal framework of 
mental suffering that not only revolves around symptoms, but also 
focuses on aspects of behaviour, functioning, psychological traits, 
somatic factors, social factors and environmental exposures, de-
pending on clinical diagnostic relevance and user preference. This 
may be productively combined with a limited number of “um-
brella” diagnostic categories at the level of the broad syndrome 
(e.g., psychosis spectrum syndrome)19.
SERVICE AND RELATIONAL EFFECTS AS 
“INVISIBLE” COMPONENTS OF TREATMENT
Just as there is methodological and statistical doubt as to 
what degree even a well-established psychotherapy like cogni-
tive-behavioral therapy (CBT) is at all effective, doubt has been 
voiced as to what degree medications like antidepressants have 
real effects24-29.
While recent meta-analytic work suggests that antidepres-
sants may have a small effect on symptoms in the short term30, 
important factors – like bias due to withdrawal symptoms in 
the placebo group and differential expectations due to the lack 
of use of active placebo in the comparison with side effect-rich 
antidepressants – remain unaddressed. In fact, one of the fac-
tors underlying the weak effects of psychotherapy and antide-
pressants as compared to placebo is the issue of expectations, 
which evidence suggests may be one of the key elements driv-
ing change in states of mental ill-health31,32.
As effect sizes of psychotherapy are small, at least in analy-
ses that take into account the many sources of bias and factors 
impacting quality26, the likelihood of meaningful differences 
between different types of psychotherapy logically must be 
similarly small, likely remaining below the threshold of statis-
tical resolution and clinical relevance. This may explain why, 
despite much research and debate, there is no meta-analytic 
evidence that well-researched psychological treatments for 
common disorders like depression, anxiety, post-traumatic 
stress disorder and borderline personality disorder show clear 
and clinically relevant differences from each other in effect size, 
regardless of the level of complexity or underlying anthropolog-
ical rationale. Instead, meta-analyses reveal the same (small) 
effects across different treatment approaches33-36.
Similarly, there is therapeutic equivalence between different 
classes of antidepressant medications37 and, although many 
guidelines suggest that clozapine may be more effective than 
other antipsychotics in treatment resistant psychotic disorder, 
the evidence on which this is based is not strong38. However, 
clozapine may be more effective than other antipsychotics in 
different outcome areas, which have been researched insuf-
ficiently but may stand out clinically.
Where it has been examined, equivalence also applies 
across pharmacological and non-pharmacological approaches, 
for example in depression39. Thus, while some specific differ-
ences between treatments may exist in low-prevalence subar-
eas of mental health, for example in anorexia nervosa40 and 
obsessive-compulsive disorder39, findings more often point to 
equivalence within and between pharmacological and non-
pharmacological treatment approaches for common mental 
disorders41.
Findings of equivalence of small effects across pharmacologi-
cal and non-pharmacological treatments may be, first, sugges-
tive of underlying heterogeneity, in the sense of some people 
responding only to treatment A and others only to treatment B, 
and all research populations representing a mix of these two and 
other types. Although this may be relevant, for example in the 
case of genetic variation underlying differences in response to 
pharmacological treatment, no reliable markers of such hetero-
geneity in response have been identified, despite much research. 
Also, in psychotherapy research, leaving out critical theoretic 
components of the therapy does not impact effect size42,43.
A stronger, although not mutually exclusive, case can be 
made for a second explanation of apparent equivalence, i.e., 
that it is not only the specific treatment itself (the “what”), but 
also generic aspects of treatments (the “how”) which impacts 
outcome. In favor of the latter is evidence of small but signifi-
cant “clinician” random effects, meaning that, under the overall 
small effect of specific treatments, reside differences between 
the particular patient-clinician mix, some being more condu-
cive to change than others, not just in psychotherapy research44 
but also, in the rare instances where it has been examined, in 
pharmacological research45.
Thus, if the “how” of treatment contributes to improvement, 
what is it? Research suggests that two aspects of the context of 
treatment may be important: a general background service- 
level effect and a patient-clinician relational effect at the level of 
the therapeutic ritual. These service-level and patient- clinician 
level contextual effects are discussed below.
Service-level contextual effects
Meta-analyses have shown that the placebo response in tri-
als of pharmacological treatments such as antidepressants46, 
antipsychotics47,48 and pain medications49 has risen over time. 
One of the factors that may contribute to the rise in placebo 
response is the change in trial context and design50. If the stan-
dard care context amounts to relative “neglect” by poorly de-
veloped services, placebo effects will approach natural course, 
and be lower compared to placebo effects in the context of 
well-developed supportive services, confounding comparisons 
between time periods and countries51. Thus, the early trials are 
more likely to reflect the comparison between natural course 
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and active treatment, whereas later trials reflect a more “ma-
ture” comparison between placebo in the context of general 
supportive treatment and the specific psychotropic agent.
The same contextual issue regarding the role of standard care 
may impact trends in psychotherapy research over time, given 
meta-analytic evidence that the efficacy of psychotherapeutic 
treatments like CBT52 has become progressively smaller over 
time. This is likely related to early trials more often including a 
“waitlist” comparison – amounting to a comparison with natural 
course – whereas later trials more often included a more active 
comparison treatment. As a result, a temporal effect will emerge 
in meta-analyses, given evidence from CBT psychotherapy trials 
that comparison with waiting-list conditions yields a substantial-
ly higher effect size than against care as usual or pill placebo25.
These temporal effects are important, as they appear to sug-
gest that having interactions with an active mental health ser-
vice brings about improvement in the same way as specific 
treatments do. It may be productive to further study this issue, 
as an optimized “general service effect” can impact many pa-
tients at the same time in a very cost-effective fashion.
Patient-clinician level contextual effects
In conditions such as depression, effects do not appear to 
differ between treatment approaches, whereas they do vary as 
a function of the specific patient-clinician mix. This observa-
tion has inspired an ongoing debate on the degree to which 
so-called “common factors” contribute to the observed phe-
nomenon of equivalence of treatments31. Common factors 
have to do with non-specific relational and ritual elements in 
the encounter between patient and clinician, such as offering 
an explanatory model, proposing a theory for change, raising 
expectations, and inspiring patient engagement, all within the 
context of a productive therapeutic relationship characterized 
by empathy, an active and caring attitude, and the capacity to 
motivate, collaborate and facilitate emotional expression.
The existence for most mental health problems of a 30-40% 
“placebo” effect, in the sense of being offered some kind of 
therapeutic ritual, and the fact that specific evidence-based 
treatments only create a small additional effect, is an argument 
in favor of the existence of common factors.
Evidence for common factors comes from research, includ-
ing some fascinating examples of experimental studies53,54, 
showing the effect of expectations32,54, the impact of therapeu-
tic relationship55, and therapist effects44. Other support comes 
from meta-analyses showing that: a) in depression, having the 
same number of psychotherapy sessions over a shorter period 
of time is more effective, suggesting an effect of the intensity of 
human contact56; b) leaving out critical theoretic components 
of psychotherapy does not impact effect size42,43 (although add-
ing components may yield a small increase)43; c) comparisons 
between active treatments and structurally inequivalent pla-
cebos produce larger effects than comparisons between active 
treatments and structurally equivalent placebos57.
Furthermore, in depression, the rise in placebo response 
over time has been accompanied by a similar rise in antide-
pressant response46. This suggests that, at least for depression, 
the “placebo” response is additive and part of the therapeutic 
response, in contrast with other areas of medicine, such as on-
cology, where placebo response constitutes a negligible part of 
the therapeutic effect (see Figure 1).
Meta-analyses of depression trials of antidepressants and 
transcranial magnetic stimulation also found a positive correla-
tion between the rate of placebo response and active treatment 
response in trials58,59. These data are compatible with the notion 
that the response to active treatment in depression is “added” to 
the placebo response or that the placebo response is an integral 
component of the treatment response. In other words, common 
factors that are part of the general therapeutic ritual may form 
the basis on which antidepressant treatment can build.
This proposition is supported by research showing that a 
“relationally warm” treatment works better than a “cold” treat-
ment53 and by studies documenting that pharmacological and 
non-pharmacological approaches reinforce each other in the 
sense of their combined effect being additive, at least in de-
pression and anxiety disorders60. In one trial, a simple focus 
on positive affect monitoring and feedback on the course of 
Figure 1 Contrasting placebo components of therapeutic effect (vertical) over time (horizontal) in psychiatry and oncology
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positive emotions was sufficient to make the antidepressant 
treatment effective61.
THE RELATIVE DISCONNECT OF DIAGNOSIS-EBP 
SYMPTOM-REDUCTION INTERVENTIONS
The delivery of evidence-based treatments focusing on 
symptom reduction should ideally serve the higher-order goal 
of social participation and existential integration (“recovery”). 
However, diagnosis-EBP symptom-reduction interventions, if 
they are available at all, are typically delivered by professionals 
who work in relative dissociation from the existential, social 
and medical needs of the patient62,63. For example, a patient 
may receive a course of CBT for hearing voices, be prescribed 
antipsychotic medication by a psychiatrist, see a social worker 
for help with housing and benefits, and visit his general practi-
tioner to receive medication for diabetes. In daily life, however, 
he may struggle with social isolation, lack of meaning, feelings 
of hopelessness and massive weight gain.
The different professionals involved in his care may know of 
each other’s existence, but have different schedules and work 
across different departments and bureaucracies, making it 
difficult to integrate their efforts. Most importantly, existential 
needs such as loneliness, meaninglessness and hopelessness 
are not addressed. While different countries and regions have 
different levels of integration of care, anecdotal evidence sug-
gests that the situation as depicted here is not rare62,63. Below, 
we discuss the issue of integration with social, existential and 
medical needs in more detail.
Integration with user knowledge and a focus on 
existential values
The diagnosis-EBP symptom-reduction perspective was 
developed in the context of a bio-psycho-social model of men-
tal health difficulties. Several novel developments, however, 
suggest that the bio-psycho-social model requires extension 
with an existential component, thus reinventing itself as a bio-
psycho-socio-existential framework in which the existential 
component is central.
First, the concept of “health” as absence of disease is risky, 
as it may result in “too much medicine, too little care”64. This 
traditional concept, therefore, is increasingly supplanted by the 
notion that health is about the ability to adjust to and manage 
medical, social and mental challenges in order to pursue life 
goals that are meaningful to the person65. In other words, res-
toration of health is not the goal, but rather the means to enable 
the patient to find and pursue meaningful goals.
Accordingly, patient existential values are becoming central 
in the practice of a novel “era 3” of evidence-informed (inter-
ventions support higher-order social and existential outcomes) 
rather than evidence-based (symptom reduction constitutes 
the core goal) medicine66,67. In this scenario, doctors naturally 
focus on existential values, practicing shared decision making 
in the sense of adjusting interventions to the existential needs 
of the patient68,69.
Of course, similar developments have been occurring in men-
tal health care, where users over the last 40 years have become 
increasingly vocal in asking for more sensitivity on the part of 
professionals for the existential domain of personal recovery, in 
the sense of helping people to overcome and adjust to the often 
extreme experience of mental vulnerability and find meaningful 
goals to live a fulfilling life, beyond the diagnosis70.
Values associated with the existential recovery perspective 
are connectedness, empowerment, identity, meaning, hope 
and optimism71,72, all reflecting the work of reinventing and 
reintegrating oneself and one’s life after experiencing the exis-
tential crisis that comes with mental illness.
While the diagnosis-EBP symptom-reduction perspective is 
not incompatible with these existential notions, there are clear 
challenges in bringing the medical “symptom reduction” and 
the existential “meaningful life” perspectives together in one 
service73,74. Although research suggests that it is possible to 
achieve growth in the existential domain in patients attending 
a psychiatric service75, the level of organizational readiness of 
traditional psychiatric services may be a rate-limiting factor in 
bringing the two perspectives together76,77.
The diagnosis-EBP model and the existential domain are 
complementary from a treatment perspective, as the former 
has its focus on the psychometric outcome of symptom re-
duction and the latter on the personal process of resilience. 
Working on resilience means a focus on things like being con-
nected to other people, narrative development, positive emo-
tions, sense of purpose, material resources and acceptance, 
requiring novel service initiatives such as a “recovery college” , 
structural peer support, “housing first” , “individual placement 
and support” , and “open dialog” , which can be difficult to im-
plement in traditional mental health services78-83.
Integration of mental, medical, substance use  
and social care
Perhaps the most persistent unresolved need for people 
with complex mental health difficulties is the lack of align-
ment between social care and medical care on the one hand, 
and mental health care and, if organized separately, addiction 
services on the other84.
People with severe mental health difficulties are more likely 
to experience a complex social situation characterized by pov-
erty, social isolation, exclusion, unemployment, stigma and 
housing needs, and more likely to die prematurely, smoke, de-
velop obesity, diabetes, addictions and other chronic condi-
tions. Meeting these needs is difficult, as they require life style 
changes for which care is allocated to different services. Optimal 
management involves collaboration between complex bureau-
cracies managing separate budgets85, giving rise to a range 
of barriers86. The available evidence suggests that the simple 
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 integration of budgets may not be enough to impact outcomes87 
and that the area of mental health care can learn from other 
health areas where such integration has been attempted88,89.
For example, integration of social and mental health care 
can focus on the creation of recovery-oriented social enter-
prises as a key component of the integrated service90. A user-
driven recovery college may be set up as a social enterprise 
using social care funding, thus in effect paying users to help 
other users achieve recovery outcomes.
Successful integration of social, existential, mental, sub-
stance use and somatic care needs to take into account the 
different echelons of clinical, service-level and public health 
approaches91. Another factor is scale. It has been suggested 
that the scale on which integration is attempted is critical, as 
integration may be best served by focusing on local networks in 
a relatively small area as a model for organizing mental health 
services92. Working together in local networks has the advantage 
of having first-name-basis interactions, creating opportunities 
for flexible needs-based consultation and joint projects in the 
area.
A small-scale area may be around 15,000 population with 
five-ten GP practices, allowing for collaboration in an “en-
hanced primary care” model of mental health services93,94.
THE PUBLIC HEALTH PERSPECTIVE
The yearly prevalence of diagnosable mental suffering is 
around 20%, whilst mental health services have the capacity 
to treat 4-6% of the population in a given year. These figures 
indicate that there is considerable scope for public mental 
health, in the sense of freely accessible sources of information, 
self-management and peer support e-communities.
A public mental health problem cannot be tackled by push-
ing the diagnosis-EBP symptom-reduction system to absurd 
limits, as evidenced by concern about overprescription of anti-
depressants95 and ADHD medication96, and increasing rates of 
involuntary admissions in European countries10.
Although much has been written about the need for a well-
developed system of public mental health alongside the tradi-
tional one-on-one mental health care system, countries have 
been slow to implement any of this15,97.
Nevertheless, in many countries, there is a growing infor-
mal network of online, self-help e-communities for people 
with a variety of mental health problems, for example, eat-
ing disorders, obsessive-compulsive disorder, psychosis and 
post-traumatic stress disorder. Although some of these have 
millions of visitors each year, and many increasingly offer 
forms of e-health and m-health solutions that can be used 
for self-management, they lack stable funding, even though it 
is increasingly recognized that they form the backbone of an 
informal public mental health system which interacts with the 
traditional mental health care system98.
A minor shift in funding from one-on-one care in the tradi-
tional diagnosis-EBP symptom-reduction mental health care 
system towards a public mental health network of complemen-
tary e-communities offering information, self-help and peer 
support, including a community-rated market of e-health and 
m-health tools that people help each other using, would bring 
a welcome balance.
E-communities are not diagnosis-specific, but vary in their 
initial presentation so as to offer people choice in seeking help 
for what is most compatible with their experience. They can not 
only help people who are not in contact with services, but also 
offer self-help and help in navigating the mental health service 
system for people already in care99.
CONSEQUENCES FOR MENTAL HEALTH SERVICES
While the specialist diagnosis-EBP symptom-reduction 
principle is dominant or even normative in the way mental 
health services are organized and evaluated, the question aris-
es to what degree it is relevant to patients. While this model has 
been productive, there is evidence that it is less than optimally 
connected to patient primary needs in the social and existential 
domains.
The expectation that the most vulnerable individuals would 
naturally reconnect with these domains, when their symptoms 
resolve, should not be taken for granted. In contrast with com-
mon mental health problems, the circularity (reversal of cause 
and effect) of symptoms, participation and existential domains 
is the core of the new “severe mental illness” definition devel-
oped by a large consensus group in the Netherlands100.
The multitude of randomized controlled trials may have 
served as trees through which the wood of the larger question, 
i.e. what patients actually require, could not be seen. In addi-
tion, while the diagnosis-EBP symptom-reduction model is 
framed in terms of technical skills and specialized knowledge, 
the evidence also indicates that a good case can be made for 
the relational and healing components of ritualized interac-
tions mediating clinical improvement.
Thus, the larger question may be how an effort can be organ-
ized to make mental health services more relevant to those who 
need them, and more in line with a critical analysis of scientific 
and experiential knowledge. This would require taking a fresh 
look at both content and organization of services, based on the 
current level of knowledge (see Table 1).
If one were to design a mental health service from scratch, 
taking into account these developments, it is likely that the new 
service would bear only moderate resemblance to the current 
system of diagnosis-EBP symptom-reduction based specialist 
services. It has been suggested that the concept of recovery may 
serve as the organizing and integrating principle for the novel 
mental health service101.
If integration and connectedness are important values, it 
may be more logical to create the mental health service on a 
relatively small scale (covering around 15,000 population), so 
as to have an authentic “look and feel” of a local healing com-
munity fostering connectedness and strengthening resilience 
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in learning to live with mental vulnerability. Peer support, for 
example, organized at the level of a recovery college, may form 
the backbone of the community.
The primary process of narrative development and finding 
and realizing meaningful goals should be supported by treat-
ments aimed at trans-syndromal symptom reduction, specifi-
cally tailored to strengthen the primary process of recovery and 
participation, and applied by professionals who have been 
trained to embrace idiography and to maximize effects medi-
ated by therapeutic relationship and aspects of the care ritual.
Education would be organized as person-centered, self-
directed, practice-based and inter-professional interaction 
between clients, students of different professions, and different 
mental health professionals, to ensure adequate development 
of attitudes, knowledge and skills in collaborating, communi-
cating and relating to each other102. Crisis intervention may be 
organized using a combination of peer-supported open dialog 
and local shelters, increasing the community capacity for social 
holding.
Some aspects of mental health services would continue to 
require a regional organization level: for example, high inten-
sive care units, medium security units, and child/youth transi-
tion psychiatric services, including “headspace”-type public 
mental health approaches103.
Importantly, the local healing community should be inte-
grated with local social care (housing, work, education), focus-
ing on recovery-oriented local social enterprises, working with 
“enhanced” local GP practices in order to integrate medical care.
The mental health service, organized as local healing commu-
nity and associated regional components, should be able to cater 
for around 4-6% of the population and have strong links with a 
public mental health system of complementary e-communities 
with capacity for up to 20% of the population, integrated with 
a user-quality rated public health “market” of e-health and m-
health tools for “blended” self-management approaches.
It is clear that the scale and complexity of the proposed change 
is such that it cannot be evaluated in a randomized controlled tri-
al. We have, therefore, suggested that it may be more productive 
to engage in a form of action-research and create a number of 
pilot projects along the lines described above and learn along the 
way104. A number of these pilot projects are currently underway, 
in the Netherlands and undoubtedly in many other countries.
A more ambitious attempt at evaluation would be to study 
pilot areas in a quasi-experimental design, with even perhaps 
randomization at the county or neighborhood level. While this 
would require considerable funding, it could be argued that it 
involves the most pressing, yet perhaps most neglected, area of 
mental health research to date.
After decades of funding of large scale efforts to delineate 
the biological mechanisms of mental illness and to conduct 
randomized clinical trials of symptom reduction strategies, that 
are not independent of legitimization issues of the academic 
professions of psychiatry and psychology, the time may have 
come to coordinate a large-scale effort around the content and 
design of (public) mental health services, taking into account 
both professional and user knowledge.
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